medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2013, Number 3

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2013; 29 (3)

Paroxysmal nocturnal hemoglobinuria: from Strübing to Eculizumab

Macía PI, García PT, Fundora ST, Fernández DN

Language: Spanish
References: 50
Page:
PDF size: 112.82 Kb.


ABSTRACT

Paroxysmal nocturnal hemoglobinuria (PNH) is a non malignant and acquired clonal disease of the hematopoietic stem cell. It is a severe and rare disease. It is the only acquired hemolytic disturbance that is caused for an erythrocyte membrane anomaly. It is a result of a somatic clonal mutation of one gene that is located in the short arm of X chromosome called phosphatidyl inositol glycan class A (PIG-A). Regulated complement proteins are identified: the decay accelerated factor (CD55) and the membrane inhibitor or reactive lysis (CD 59); the abnormal blood cells of PNH have deficiency of these two proteins. PNH is classified in: classic PNH, PNH associated with another bone marrow disturbance and PNH sub clinic. Diagnosis is obtained by hematological, biochemical, kinetics and imagenologics studies and serologic special tests. High resolution membrane protein electrophoresis and flow cytometry are the elective tests. Treatments for anemia, thrombotic episodes and infections are important in the management of these patients. Steroids, androgens, human recombinant erythropoietin and granulocytic colony stimulating factor (CSF-G) are the more used pharmacology agents. Recently, the monoclonal antibody eculizumab has increased the life expectation in these patients with a better quality of life.


REFERENCES

  1. Morado M, Subirá D, López M. Hemoglobinuria paroxística nocturna: nuevos tratamientos y recomendaciones generales para su diagnóstico. Med Clin 2010; 134(8):369-74.

  2. Luzzatto L, Risitano AM, Notaro R. Paroxysmal nocturnal hemoglobinuria and eculizumab.Haematologica 2010; 95(4):523-6.

  3. Guía clínica HPN. Consenso Español para Diagnóstico y tratamiento de la Hemoglobinuria Paroxística Nocturna. Sociedad Española de HEmatolog{ia y Hemoterapia.SEHH. 2010. Disponible en:http://www.sehh.es/documentos/42/HPN_guia_clinica_v17.pdf

  4. Brodsky RA. New inside into Paroxysmal Nocturnal Hemoglobinuria. Hematology (internet). Enero 2006 (citado septiembre 2012); 24(8): [aprox. 5 p]. Disponible en:http://asheducationbook.hematologylibrary.org/content/2006/1/24.full.pdf+htm

  5. García-Conde J. Hematología. Madrid: Ediciones Arán; 2003.p.737-42.

  6. Parker CJ. Paroxismal Nocturnal Hemoglobinuria. Curr Opin Hematology. 2012;19:141 8. DOI: 10.1097/MOH.0b013c32835/c348.

  7. Rodak BF. Hematología. Fundamentos y aplicaciones clínicas.2a ed. Buenos Aires: Editorial Médica Panamericana. 2004; p.286-94

  8. Milanés MT, Fernández N, Fundora T, Facundo JC, Hernández P. Hemoglobinuria paroxística nocturna. Actualización. Revista Cubana de Hematología, Inmunología y Hemoterapia (internet). Enero Abril 2003 (citado septiembre 2012); 1(19): [aprox. 5 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864 - 02892003000100001&lng=es&nrm=iso&tlng=es

  9. Rosti V. The molecular basis of paroxysmal nocturnal hemoglobinuria. Haematologica.2000; 85: 82-9.

  10. Luzzato L, Bessler M. The dual pathogenesis of paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol.1996;3:101-10.

  11. Johnson RJ, Hillmen. Paroxysmal nocturnal hemoglobinuria. Mol Pathol 2002; 55:145-52.

  12. Rosse WF. Paroxysmal nocturnal hemoglobinuria. En: Hoffman R, Benz EJ, Shatill SJ, Furie B, Cohen HJ, Silberstein E, McGlave P. Hematology: Basic principles and practice. 3 ed. USA: Churchill Livingstone. 2000; p. 331-42.

  13. Yoon JH, Cho HI, Park SS, Chang YH, Kim BK. Mutation analysis of the PIG-A gene in Korean patients with paroxysmal nocturnal haemoglobinuria. J. Clin Pathol. 2002;55:410-3.

  14. Prusiner SB, Scott MR, De Armond SJ, Cohen FE. Prion protein biology. Cell 1998;93:337-48.

  15. Caughey B, Raymond GJ. The scrapie-associated form of PrP is made from a cell surface precursor that is both protease and phospholipase-sensitive. J Biol Chem 1991;266:18217-23.

  16. Dodelet VC, Cashman NR. Prion expression in human leukocyte differentiation. Blood 1998;91:1556-61.

  17. Meletis J, Terpos E. Paroxysmal nocturnal hemoglobinuria: clinical presentation and association with other haematological disorders. Haema 2001;4:79-88.

  18. Richard-Lee G. Hemoglobinuria paroxística nocturna. En: Wintrobe Hematología Clínica. 9 ed. Editorial Inter-Médicos S.A.I.C.I. 1994; p.1072-83.

  19. Ray JG, Burows RF, Ginsberg JS, Burrows EA. Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: review and non pregnant patient. Haemostasis 2000;30:103-17.

  20. Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:3699709.

  21. Hernández-Campo PM, Almeida J, López A, Orfao A. Hemoglobinuria paroxística nocturna. Med Clin(Barc).2008;131:61730.

  22. De Latour RP, Mary JY, Salanoubat C,Terriou L,Etienne G,Mothy M, et al. Paroxysmal nocturnal hemoglobinuria: Natural history of disease subcate- gories. Blood.2008; 112(4):3099106.

  23. Meletis J, Terpos E, Samarkos M. Detection of CD55 and/or CD59 deficient red cell population in patients with aplastic anemia, myelodysplastic syndrome and myeloproliferative dirsoders. Haematología 2001;31:7-16.

  24. Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106: 3699709.

  25. Richards SJ, Rawstron AC, Hillmen P. Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry Part A. 15 de Agosto 2000 (citado septiembre 2012); 4(42): (aprox. 10 p.). Disponible en: http://onlinelibrary.wiley.com/doi/10.1002/1097- 0320%2820000815%2942:4%3C223::AID-CYTO2%3E3.0.CO;2-D/full

  26. Richards SJ, Barnett D. The role of flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria in the clinical laboratory.Clin Lab Med. 2007;27: 57790.

  27. Risitano Antonio M, Rotoli Bruno. Paroxismal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents. Biologics. Junio 2008; 2(2): 205 - 222.

  28. Rother RP, Bell L, Hillmen P,Gladwin M T. The clinical sequelae of intravascular hemolysis and extracelular plasma hemoglobin: A novel mechanism of human disease. The Journal of the American Medical Association (JAMA). Abril 2005; 293 (15):1653 - 1662.

  29. Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood. Abril 2009; 113(26): 6522-6527.

  30. Luzzato L, Gianfaldoni G, Notaro R. Management of Paroxysmal Nocturnal Haemoglobinuria: a personal view. Br J Haematol 2011; 153:709-720. doi: 10.1111/j.1365-2141.2011.08690.x

  31. Brodsky RA. Stem cell transplantation for paroxysmal nocturnal Hemoglobinuria. Haematologica 2010; 95(6): 855-6.

  32. Matos- Fernández NA, Abou Mourad Y, Caceres W. Current Status of allogenis hematopoietic stem cell transplantation for paroxismal nocturnal hemoglobinuria. Biol Blood Marrow Transplant 2009; 15(6):656-61. doi: 10.1016/j.bbmt.2008.12.507

  33. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal Hemoglobinuria. Nat Biotech, 2007;25: 1256-64.

  34. Kelly R, Arnold L, Richards S, Hill A, Bomken C, Hanley J et al. the management of pregnancy in paroxysmal nocturnal Hemoglobinuria of long term eculizumab. Br J Haematol 2010; 149(3):446-50.

  35. Luzatto L, Gianfaldoni G. Recent advances in biological and clinical aspects of paroxysmal nocturnal Hemoglobinuria. Int J Haematol 2006; 84: 104-12

  36. Caro P, García Y. Estudio eritrocinético en la hemoglobinuria paroxística nocturna. Sangre 1979;24: 627-32

  37. Fundora T, García Y, Roque MC, Vidal H, Ferrer R, González A. Incorporación de la transferrina al eritrón en estados anémicos y policitémicos. Sangre 1991;36: 187-91

  38. Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet. 2009;373: 75967.

  39. Hillmen P,Muus P, Duhrsen U, Risitano AM, Schubert J, Luzzatto L, et al. Effect on the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.Blood.2007;110:41238.

  40. Hillmen P. The role of complement inhibition in PNH. Hematology Am Soc Hematol Educ Program.2008; 1:11623.

  41. Hill A, Ridley SH, Esser D, Oldroyd RG, Cullen MJ, Kareclas P,et al. Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant solubleCD59:A new approach to PNH therapy.Blood. 2006;107: 21317.

  42. Richards SJ, Whitby L,Cullen MJ, Dickinson AJ, Granger V, Reilly JT, et al. Development and evaluation of a stabilized whole-blood preparation as a process control material for screening of paroxysmal nocturnal hemoglobinuria by flow cytometry.CytometryBClinCytom.2009;79B:4755.

  43. Wang SA, Pozdyakova O, Jorgensen JL, Medeiros J, Stachurski D, Anderson M, et al. Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveats.Haematologica.2009; 94: 2937.

  44. Algado JT, Luque R, Núñez R, Sánchez B. Infección meningocócica probable en paciente con hemoglobinuria paroxística nocturna y tratamiento con eculizumab. Enferm Infecc Microbiol Clin. 2012;30:109-10.

  45. Provan D, Gribben E.J. Ed. Molecular Hematology. 3th ed. Oxford: Wiley Blackwell. 2010.

  46. De Guibert S, de Latour RP, Varoqueaux N, Labussiere H, Bernard R, Jaulmes D et al. paroxysmal nocturnal Hemoglobinuria and pregnancy before the eculizumab era: the French experience. Haematologica 2011;96(9): 1276-1283. doi: 10.3324/haematol.2010.037531.

  47. Brodsky RA. Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Shubert J, et al. Multicentrc phase 3 study of the complement inhibitor eculizumab for the treatment of patient with paroxysmal nocturnal Hemoglobinuria. Blood. 2008; 11:1840-7

  48. Brodsky RA. Paroxysmal nocturnal hemoglobinuria: Stem cell and clonality. Hematology Am Soc Hematol Educ Program.2008; 1:1115. 11.

  49. Sutherland DR, Kuek N, Davidson J, Barth D, Chang H, Eo E, et al. Diagnosing PNH with FLAER and multiparameter flow cytometry. Cytometry B Clin Cytom. 2007; 72B:16777.

  50. Oelschlaegel U, Besson I, Arnoulet C, Sainty D, Nowak R, Naumann R, et al. A standarized flow cytometric method for screening paroxysmal nocturnal hemoglobinuria (PNH) measuring CD55 and CD59 expression on erythrocytes and granulocytes.Clin Lab Haem.2001;23:8190.




2020     |     www.medigraphic.com